Meeting
2022 ASCO Annual Meeting
SALVO: Single-arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
Authors
Lisa A. Kottschade
Mayo Clinic, Rochester, MN
Lisa A. Kottschade , Gregory Russell Pond , Anthony J. Olszanski , Yousef Zakharia , Evidio Domingo-Musibay , Ralph J. Hauke , Brendan D. Curti , Sarah Schober , Mohammed M. Milhem , Matthew Stephen Block , Robert R. McWilliams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03241186
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9573)
DOI
10.1200/JCO.2022.40.16_suppl.9573
Abstract #
9573
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
SALVO: Single-arm phase II study of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma.
First Author: Robert R. McWilliams
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2014 ASCO Annual Meeting
The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma.
First Author: Christiana Bitas
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin